How can better identification of T790M help to inform treatment sequencing decisions in EGFR mutation-positive non-small-cell lung cancer?

Future Oncol. 2019 Sep;15(25):2895-2898. doi: 10.2217/fon-2019-0142. Epub 2019 Apr 29.

Author

Maximilian J Hochmair¹

Affiliation

¹ Department of Respiratory & Critical Care Medicine & Ludwig Boltzmann Institute for COPD & Respiratory Epidemiology, Otto Wagner Hospital, 1140 Vienna, Austria.

PMID: 31030557
DOI: 10.2217/fon-2019-0142

No abstract available

Keywords: EGFR; T790M; sequencing.

MeSH terms

Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / genetics
Drug Resistance, Neoplasm*
ErbB Receptors / genetics
Humans
Mutation
Protein Kinase Inhibitors / therapeutic use*

Substances

Protein Kinase Inhibitors
EGFR protein, human
ErbB Receptors